Scott Bizily Sells 1,996 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,996 shares of the firm’s stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $25.00, for a total transaction of $49,900.00. Following the transaction, the insider now owns 6,781 shares of the company’s stock, valued at approximately $169,525. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Scott Bizily also recently made the following trade(s):

• On Monday, July 1st, Scott Bizily sold 4,248 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $21.36, for a total transaction of $90,737.28.
• On Thursday, May 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $25.45, for a total transaction of $44,537.50.
• On Tuesday, April 16th, Scott Bizily sold 1,750 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $25.74, for a total value of $45,045.00.

4D Molecular Therapeutics Trading Down 1.1 %

Shares of 4D Molecular Therapeutics stock traded down $0.29 on Monday, hitting $26.93. 626,795 shares of the company traded hands, compared to its average volume of 851,536. 4D Molecular Therapeutics, Inc. has a 12-month low of $9.44 and a 12-month high of $36.25. The company has a 50-day moving average price of $23.95 and a 200 day moving average price of $24.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 9th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.07. The firm had revenue of $0.03 million for the quarter, compared to analyst estimates of $1.44 million. As a group, sell-side analysts forecast that 4D Molecular Therapeutics, Inc. will post -2.98 EPS for the current fiscal year.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Large investors have recently made changes to their positions in the company. Opaleye Management Inc. lifted its stake in 4D Molecular Therapeutics by 11.5% in the first quarter. Opaleye Management Inc. now owns 344,123 shares of the company’s stock valued at $10,964,000 after acquiring an additional 35,623 shares during the last quarter. RA Capital Management L.P. lifted its stake in shares of 4D Molecular Therapeutics by 21.3% in the 1st quarter. RA Capital Management L.P. now owns 5,051,511 shares of the company’s stock valued at $160,941,000 after purchasing an additional 888,300 shares during the last quarter. Zimmer Partners LP acquired a new position in 4D Molecular Therapeutics during the first quarter worth $4,422,000. California State Teachers Retirement System raised its holdings in 4D Molecular Therapeutics by 12.6% during the first quarter. California State Teachers Retirement System now owns 28,490 shares of the company’s stock valued at $908,000 after buying an additional 3,197 shares in the last quarter. Finally, Janus Henderson Group PLC increased its holdings in shares of 4D Molecular Therapeutics by 3.4% during the 1st quarter. Janus Henderson Group PLC now owns 3,197,444 shares of the company’s stock valued at $101,844,000 after acquiring an additional 104,148 shares during the last quarter. Institutional investors own 99.27% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Jefferies Financial Group boosted their target price on 4D Molecular Therapeutics from $30.00 to $58.00 and gave the stock a “buy” rating in a research report on Monday, April 1st. BMO Capital Markets reduced their price objective on shares of 4D Molecular Therapeutics from $70.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, April 1st. HC Wainwright reiterated a “buy” rating and issued a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Friday, June 7th. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a report on Monday, April 15th. They set an “overweight” rating on the stock. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 price objective on shares of 4D Molecular Therapeutics in a research report on Wednesday, June 26th. Ten research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $45.63.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.